IMD-0354 is an inhibitor of IκB kinase-β (IKKβ) that blocks NF-κB nuclear translocation. Attenuates myocardial ischemia/reperfusion injury by decreasing expression of adhesion molecules ICAM-1 and P-selectin and inhibiting cytokine and chemokine production in cardiomyocytes. Induces G0/G1 cell cycle arrest and apoptosis in HMC-1 and breast cancer cells. IMD-0354 had been in phase I clinical trials for the treatment of atopic dermatitis.

Aminothiazole is a heterocyclic amine, commonly used as a starting point for synthesis of many compounds. In 1940s aminothiazole was used for the treatment of thyrotoxicosis. It has a direct action on the thyroid and acts by inhibiting T4 synthesis and accelerating its deiodination. Aminothiazole is an inhibitor of inducible NO synthetase (IC50 18 uM).

Aminothiazole is a heterocyclic amine, commonly used as a starting point for synthesis of many compounds. In 1940s aminothiazole was used for the treatment of thyrotoxicosis. It has a direct action on the thyroid and acts by inhibiting T4 synthesis and accelerating its deiodination. Aminothiazole is an inhibitor of inducible NO synthetase (IC50 18 uM).